



U.S. Department of Justice
Federal Bureau of Prisons

Health Services Division

Washington, D.C. 20534

January 5, 2022

**MEMORANDUM FOR ALL CHIEF EXECUTIVE OFFICERS
ALL HEALTH SERVICE ADMINISTRATORS
ALL INSTITUTION CHIEF PHARMACISTS**

FROM:

(b)(6); (b)(7)(C)
Health Services Division

(b)(6); (b)(7)(C)

Digitally signed by (b)(6); (b)(7)(C)
Date: 2022.01.05 12:06:37 -0500

SUBJECT:

Clinical Guidance on COVID-19 Outpatient
Therapeutics

The Health Services Division (HSD) recently updated the Clinical Guidance on COVID-19 Outpatient Therapeutics (formerly titled Monoclonal Antibody Therapy for COVID-19), January 2022. The guidance is issued for immediate implementation throughout the Bureau of Prisons (BOP). It will soon be available on the Sallyport COVID-19 Resources page.

This update has been issued to reflect changes to the Emergency Use Authorization (EUA) of several monoclonal antibody therapies. In addition to their indication for treatment of mild to moderate COVID-19 in patients at risk for severe illness, the FDA has approved or expanded the EUA for several monoclonal antibodies to include use as pre or post exposure prophylaxis of COVID-19 in individuals who meet the criteria listed in the EUA. Due to rapid mutations of the SARS-CoV-2 virus, available treatment options may not always be effective for the prevailing variant in BOP institutions. Providers should be aware of the predominant variant in their local area and review the Antiviral Resistance information in Section 15 of the applicable EUA Fact Sheet for Health Care Providers for details regarding specific variants and resistance. Institutions are reminded that the therapeutic options reviewed in this guidance are available by request through the CFAD.

Thank you for your ongoing commitment to providing quality health care to the BOP inmate population. If you have any questions regarding these guidelines, please contact RADM

(b)(6); (b)(7)(C)

(b)(6); (b)(7)(C)

(b)(6);
(b)(7)(C)

Cc: M.D. Smith, Assistant Director
RADM Chris A. Bina, PharmD, Sr. Deputy Assistant Director
(b)(6); (b)(7)(C)
(b)(6); (b)(7)(C) Clinical Pharmacy Program
(b)(6); (b)(7)(C) Health Programs
Regional Medical Directors
HSD Branch Chiefs
HSD Chief Professional Officers
Regional Hepatitis Clinical Pharmacist Consultants
Regional HIV Clinical Pharmacist Consultants
Medical Asset Support Team Members